AIM This study aims to evaluate the effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus (T2D). METHODS This is a multicenter, open-labeled, randomized controlled study. T2D patients with HbA1c 6.9-8.9% (52-74 mmol/mol) who were under treatment with sulfonylurea were randomly allocated to either the sitagliptin group or the non-sitagliptin group. Glucose and lipid metabolism parameters including apolipoproteins (apo), sterols, and urinary albumin were assessed at baseline, 3, and 6 months of the treatment. RESULTS A total of 164 patients completed the 6-month observation (n = 81 for sitagliptin and n = 83 for non-sitagliptin). HbA1c decreased in the sitagliptin group but not in the non-sitagliptin group. Serum TG and total, LDL and HDL cholesterol levels did not change in either group. Apo B-48, apo CII, and apo CIII levels decreased in the sitagliptin group, but not in the non-sitagliptin group. The change in urinary albumin was significantly different between the groups with a preferable change in the sitagliptin group. There were no changes in serum sterols levels in the two groups. CONCLUSIONS The treatment of sitagliptin for 6 months improves the metabolism of glucose and chylomicron and reduces plasma levels of atherogenic lipoproteins in patients with T2D.

中文翻译：

---

西他列汀改善2型糖尿病患者的血浆载脂蛋白谱：西他列汀对脂质和葡萄糖代谢（SLIM）影响的一项随机临床试验。

目的本研究旨在评估二肽基肽酶-4抑制剂对2型糖尿病（T2D）患者脂质代谢的影响。方法这是一个多中心，开放标签，随机对照研究。将接受磺酰脲治疗的HbA1c 6.9-8.9％（52-74 mmol / mol）的T2D患者随机分配至西他列汀组或非西他列汀组。在治疗的基线，治疗3个月和6个月时评估了包括载脂蛋白（apo），固醇和尿白蛋白在内的葡萄糖和脂质代谢参数。结果共有164位患者完成了6个月的观察（西他列汀组n = 81，非西他列汀组n = 83）。西他列汀组的HbA1c下降，但非西他列汀组的HbA1c下降。两组的血清TG，总LDL和HDL胆固醇水平均未改变。西他列汀组中Apo B-48，apo CII和apo CIII的水平下降，但非西他列汀组中没有下降。各组之间尿白蛋白的变化显着不同，西他列汀组的变化最好。两组的血清固醇水平无变化。结论西他列汀治疗6个月可改善T2D患者的葡萄糖和乳糜微粒的代谢，并降低血浆中动脉粥样硬化脂蛋白的水平。